Toronto, Ontario -November 12, 2012 -- Theralase Technologies Inc. (TSX-V: TLT) Photo Dynamic Therapy (PDT) Division, announced today study results proving that its patented Photo Dynamic Compounds (PDCs) were significantly more effective in destroying a human urinary bladder carcinoma cell line than a FDA approved photosensitizer, aminolevulinic acid (ALA).
Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated, "Commercialization of any new anti-cancer medicine depends upon the safe and effective destruction of all cancerous tumours, while upholding the patient's quality of life. We are excited that our leading compound effectively destroyed a human urinary bladder carcinoma cell line (HT-1376) when activated by our proprietary light system. To validate our initial success, we evaluated the efficacy of the Theralase PDC in comparison with aminolevulinic acid (ALA). The results indicated that the Theralase PDC was effectively destroying bladder cancer cells at much lower concentrations than ALA (1/1000th of the dose)."
Dr. Lothar Lilge, Professor and Senior Scientist, Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network stated, "In my lab, the Theralase PDCs have shown remarkable efficacy and robustness in the destruction of various cancer cell lines, such as: colon, brain, breast and now bladder cancer. This research potentially offers a new opportunity for individualized cancer therapy across various invasive tumours."
Roger Dumoulin-White, President and CEO, Theralase Inc. stated, "Based upon our recent success, we have now reconfirmed that bladder cancer is our lead cancer target for our lead PDC compound. Our research confirms what we had already suspected; our PDC technology is lethal to human urinary bladder carcinoma cells. Given that our technology can deliver effective results at significantly lower doses than ALA, this would suggest a superior safety and cost effectiveness for our lead compound, as compared to ALA. We are confident that as we complete our preclinical research and prepare for human trials in 2013, we will demonstrate to the medical community that we possess a highly effective, safe and efficient alternative treatment option to current bladder cancer patients."
Bladder cancer is the fifth most common cancer in the North America; the fourth most common among men and eighth most common in women. In the United States 73,000 new bladder cancer cases and 15,000 deaths are reported annually. With a recurrence rate of nearly 80%, bladder cancer is the most expensive cancer to treat on a per patient basis. The high recurrence rate severely affects the quality of life of patients and also the total cost of treatment, which in the United States exceeds $2.9 billion in direct treatment related costs annually.
In other related news, Sun Pharmaceutical Industries (NSE: SUNPHARMA, BSE: 524715), with a market value of $USD 13.3 billion, announced on November 8, 2012, that it signed a definitive agreement to acquire Dusa Pharaceuticals Inc. (DUSA) for $8 per share for a total cash consideration of $USD 230 million. DUSA is a dermatology company focused on developing and marketing its FDA approved Levulan photodynamic therapy platform (active ingredient of Levulan is ALA), for actinic keratosis of the face or scalp (dry, scaly patches on the skin that can lead to skin cancer). http://www.sunpharma.com/news/press/20121108%20Sun%20Pharma%20to%20Acquire%20DUSA%20.pdf
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase's proprietary and patented laser technology.
For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information
President & CEO
416-447-8455 ext. 225
Chief Financial Officer
416-447-8455 ext. 224
Chief Scientific Officer
416-447-8455 ext. 242
Director of Investor Relations
416-447-8455 ext. 262